Lilly has secured FDA approval for its innovative weekly insulin, Onswik, offering a new alternative for adults with type 2 diabetes seeking to minimise daily injections and streamline their treatment regime.
The U.S. Food and Drug Administration has approved Eli Lilly’s once-weekly insulin efsitora alfa-gobe, sold as Onswik, for adults with type 2 diabetes, adding a new option for people whose blood sugar remains difficult to control despite diet and exercise. The agency said the drug should be taken by injection once a week on the same day each week, and stressed that it is not recommended for people with type 1 diabetes because of the risk of severe hypoglycaemia.
The approval is backed by Lilly’s QWINT phase 3 programme, which involved more than 3,400 adults with type 2 diabetes across four global studies. According to the company and the FDA, Onswik met the main efficacy goal in each trial by lowering HbA1c, the laboratory measure that reflects average blood sugar over roughly two to three months, by an amount that was non-inferior to established daily basal insulins, including insulin glargine U-100 and insulin degludec U-100.
Lilly says the weekly formulation is designed to maintain basal insulin coverage over seven days, with the aim of cutting treatment burden for patients who currently inject insulin every day. The company estimates that the regimen could mean roughly 52 injections a year instead of 365, a difference it argues may matter for people who struggle with delays in starting insulin or with the cumulative inconvenience of daily dosing. The FDA described Onswik as the second once-weekly insulin approved for adults with type 2 diabetes, underscoring how unusual the category still is.
The safety profile seen in the trials was described as broadly similar to that of the daily basal insulins used for comparison. Reported side effects include low blood sugar, allergic reactions, injection-site reactions, lipodystrophy, itching, rash, swelling of the hands and feet, and weight gain. Lilly has also said Onswik has already won regulatory clearances in the European Union, Mexico and Japan, making the US decision its fourth global approval, while its KwikPen delivery device is expected to be available in the coming months in two concentrations.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
